Small Science Materials Science (miscellaneous)
Piperine Nanoparticles Significantly Improved Fragile X–Associated Tremor/Ataxia Syndrome via Mitigating RNA and Repeat‐Associated Non‐AUG Toxicities
Abstract
Fragile X–associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder driven by fragile X messenger ribonucleoprotein 1 ( FMR1 ) premutation CGG repeats on the X chromosome, causing RNA and repeat‐associated non‐AUG (RAN) toxicities. Although piperine demonstrated preliminary mitigation of RNA toxicity, its poor aqueous solubility restricted further development. The current study evaluated piperine nanoparticles (PIP NPs) with enhanced solubility for FXTAS management. Briefly, PIP NPs were prepared using flash nanoprecipitation followed by assessing their impact on both CGG repeat Drosophila and mouse models. PIP NPs could significantly ameliorate the climbing deficits, protect against early‐stage mortality (100 μM) and preserve retinal integrity in CGG repeat Drosophila , and rescue motor coordination and abnormal learning conditioning in CGG repeat mice, while reducing toxic FMR1 mRNA, restoring Drosophila fragile X messenger ribonucleoprotein 1 (dFmr1) or fragile X messenger ribonucleoprotein (FMRP) expression, suppressing FMRpolyG‐GFP production in Drosophila , and mitigating ubiquitin‐positive intranuclear inclusions. Based on the findings, molecular docking analyses were adopted to provide a computational structural rationale for the proposed interactions between piperine and DExH‐box helicase 9 (DHX9)/death‐associated protein 5 (DAP5)/heat shock protein 70 (Hsp70). The serial in vitro, in vivo, and in silico investigations consistently demonstrated PIP NPs as a promising therapeutic candidate for FXTAS.